ARTICLE
19 September 2022

EPA Renews Biotechnology Innovation Efforts Under New Executive Order

BD
Beveridge & Diamond

Contributor

Beveridge & Diamond’s more than 125 lawyers across the U.S. offer decades and depth of experience advising numerous industry sectors on environmental law and its changing applicability to complex businesses worldwide. Our core capabilities encompass facilities and products; U.S. and international matters; regulatory strategy, compliance, and enforcement; litigation; and transactions.
On September 12, 2022, President Biden issued an Executive Order (EO) calling on his Administration to renew efforts to improve the clarity and efficiency of regulatory processes...
United States Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

On September 12, 2022, President Biden issued an Executive Order (EO) calling on his Administration to renew efforts to improve the clarity and efficiency of regulatory processes for biotechnology products. Launching a new "National Biotechnology and Biomanufacturing Initiative," the EO is intended to advance policies that promote innovative biotechnology and biomanufacturing solutions in "health, climate change, energy, food security, agriculture, supply chain resilience, and national and economic security."

Among its directives, the EO calls on the U.S. Environmental Protection Agency (EPA), the U.S. Department of Agriculture (USDA), and the U.S. Food and Drug Administration (FDA) to identify areas of ambiguity, gaps, or uncertainties in the January 2017 Update to the Coordinated Framework for the Regulation of Biotechnology and EO 13874, Modernizing the Regulatory Framework for Agricultural Biotechnology Products. Specifically, the EO charges the agencies with:

  • Providing plain-language information to the public regarding the regulatory roles, responsibilities, and processes of each agency as they relate to biotechnology products;
  • Identifying regulations and guidance that they can update, streamline, or clarify; and
  • Providing annual updates to identify gaps in statutory authority to address in order to improve the clarity and efficiency of the regulatory process for biotechnology products.

The EO also directs EPA, USDA, and FDA to build on the Unified Website for Biotechnology. The website update will allow developers of biotechnology products to inquire about a particular product and promptly receive a single, coordinated response providing information and informal guidance regarding the process that the developers must follow for Federal regulatory review.

In addition, the EO requires USDA to assess how to use biotechnology and biomanufacturing for food and agriculture innovation. Issues USDA will evaluate include improving sustainability and land conservation, increasing food quality and nutrition, increasing and protecting agricultural yields, protecting against plant and animal pests and diseases, and cultivating alternative food sources.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

ARTICLE
19 September 2022

EPA Renews Biotechnology Innovation Efforts Under New Executive Order

United States Food, Drugs, Healthcare, Life Sciences

Contributor

Beveridge & Diamond’s more than 125 lawyers across the U.S. offer decades and depth of experience advising numerous industry sectors on environmental law and its changing applicability to complex businesses worldwide. Our core capabilities encompass facilities and products; U.S. and international matters; regulatory strategy, compliance, and enforcement; litigation; and transactions.
See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More